Overview

Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis B

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to provide data of absence of inflammation in patient liver histology after long-term telbivudine treatment and thus help investigators to make a comprehensive judgment on treatment discontinuation in selected patients

Phase:

Phase 4

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Telbivudine